Johnson & Johnson JNJ

271.22 0.54 0.20% as of 25 Sep
Market cap
$652.8B
P/E
31.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Johnson & Johnson (JNJ) Revenue growth

Johnson & Johnson's revenue growth over the twelve months to 30 June 2026 was 8.06%, up 2.0 percentage points from fiscal 2025 (6.05%). Over the past ten years it has ranged from −5.73% (fiscal 2015) to 6.71% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 6.79% and in line with the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 6.05% 1.75
FY2024 4.30% (2.16)
FY2023 6.46% 4.87
FY2022 1.59% 6.24
FY2021 −4.65% (5.29)
FY2020 0.64% 0.05
FY2019 0.59% (6.12)
FY2018 6.71% 0.37
FY2017 6.34% 3.75
FY2016 2.59% 8.32

Quarterly

Period Revenue growth Change (points)
Jun 2026 6.60% (3.31)
Mar 2026 9.91% 0.83
Dec 2025 9.08% 2.31
Sep 2025 6.77% 1.00
42 more quarters

Against its own ten years

Low −5.73% High 6.71%
Ten-year median 2.59%
Current reading's percentile 73

Revenue growth against peers

Company Revenue growth
LLY Eli Lilly and Company compare 49.6%
ABBV AbbVie Inc. compare 10.4%
AMGN Amgen Inc. compare 9.10%
AZN AstraZeneca PLC compare 8.61%
JNJ Johnson & Johnson 8.06%
GILD Gilead Sciences, Inc. compare 5.52%
MRK Merck & Co., Inc. compare 4.64%
NVS Novartis AG compare 2.73%
PFE Pfizer Inc. compare −0.21%
Drug Manufacturers General industry median 6.79%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on JNJ